Related Experiment Video
Updated: Nov 2, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Practical Considerations for Integrating Biosimilars Into Clinical Practice
Megan B May1, Kate Deen Taucher2, Wendy H Vogel3
1Baptist Health Lexington, Lexington, Kentucky.
Abstract:
The development of innovator biologics and now their biosimilars has created some unique challenges in oncology practice. The oncology advanced practitioner (OAP) must understand the key differences between the innovator biologic and biosimilars in regard to efficacy, safety, and immunogenicity. In addition, the OAP must be able to evaluate and successfully navigate factors that may affect the adoption of biosimilars, such as the perceived cost-benefit and clinician and patient acceptance.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Bioequivalence: Overview
Bioequivalence of Drugs: Drugs with Multiple Indications
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Bioavailability Study Design: Healthy Subjects Versus Patients

